1. Is Pfizer’s established drugs’ decline in China a canary in a coalmine? — Amgen biosimilar debut boosted by UnitedHealthcare coverage — Novartis CEO says FDA process could’ve been handled better — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. What happened a year ago this week in biopharma? Regeneron’s Eylea approval, Novartis’ new ethics czar, Vertex’s Kalydeco, and Opidvo’s SCLC approval click to review and read a current update of the big stories from one year ago
    Dismiss Notice

Re-Opening

Discussion in 'Atherotech' started by anonymous, May 24, 2016 at 1:09 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Rumors of a re-opening keep popping up from people I meet that knew I worked there. You might have to be crazy to entertain going back. It would have to be rebuilt from scratch with no clients. Anyone else hearing this craziness?
     
  2. anonymous

    anonymous Guest

    Yes, it's called Compass Labs aka Atherotech version II. Rumor has it that they layed off their shipping dept. yesterday.
     
  3. anonymous

    anonymous Guest

    What happens when they over hire and bring on management who like to hire useless people that bring zero value! This makes me laugh!!!!!